Clinical trial
A Phase 2 Randomized, Double-blind and Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia
NCT06571448 is registered in ClinicalTrials.gov with Shanghai SIMR Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-blind and Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia
- Lead sponsor
- Shanghai SIMR Biotechnology Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 16, 2024
- Completion date
- February 24, 2026
- Enrollment
- 138 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.